{"filings":[{"id":93859,"accession_number":"0001493152-26-018575","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Hepion Pharmaceuticals raises $700,000 in private placement of 17.5 million shares","event_type":"other_material","confidence":"high","bullets":["Hepion entered securities purchase agreements with accredited investors on April 21, 2026, selling 17,500,000 shares at $0.04 per share.","Gross proceeds from the private placement were $700,000, and the offering closed on the same date.","The shares were issued in reliance on exemptions under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.","Gary Stetz, Interim CEO, signed the 8-K filing on behalf of Hepion Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93858,"accession_number":"0001493152-26-016557","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["1.01","5.02"],"status":"ready","headline":"Hepion Pharma CEO Kaouthar Lbiati resigns; separation agreement provides $225K payment","event_type":"leadership","confidence":"high","bullets":["Separation agreement pays Dr. Lbiati $225,000, $30,625 pro-rata bonus, and 6 months COBRA reimbursement.","Lbiati resigned as CEO on March 16, 2026, and as director on April 13, 2026.","Gary Stetz serves as Interim CEO effective from the separation date.","Separation includes a general release and confidentiality covenant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105818,"accession_number":"0001493152-26-011222","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hepion Pharma CEO Kaouthar Lbiati resigns; Gary Stetz named interim CEO","event_type":"leadership","confidence":"high","bullets":["CEO Dr. Kaouthar Lbiati resigned effective March 16, 2026, for personal reasons.","Board appointed Gary Stetz as interim CEO and director; Vincent LoPriore as Executive Chairman.","Sireesh Appajosyula and Chase LoPriore also appointed to the board of directors.","No family relationships or arrangements between new appointees and other officers disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105817,"accession_number":"0001493152-26-008650","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Hepion in-licenses ctRNA biomarker assay for early HCC detection from Cirna Diagnostics","event_type":"other_material","confidence":"high","bullets":["Upfront $50K, milestones up to $2.35M, sales milestones up to $4.5M, low single-digit royalty.","Assay detects mutant circulating tumor RNA (ctRNA) for early HCC diagnosis in high-risk cirrhosis patients.","Complements Hepion's mSEPT9 PCR assay; strategic shift to liquid biopsy diagnostics.","Global liquid biopsy market ~$10B; plans CLIA lab partnerships and eventual FDA submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105816,"accession_number":"0001493152-26-002428","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hepion Pharmaceuticals names Kaouthar Lbiati CEO effective Jan 8, 2026; salary $350K","event_type":"leadership","confidence":"high","bullets":["Dr. Kaouthar Lbiati appointed CEO effective Jan 8, 2026, per Board approval on Jan 13, 2026.","Annual base salary $350,000; $50,000 deferred until equity financing ≥$3M, termination, or change of control.","Annual cash bonus target 35% of base salary based on Board-set goals.","Change-of-control bonus: 3% of enterprise value if ≥$5M.","Severance: 6 months base plus bonus upon termination without cause or good reason; equity acceleration provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156257,"accession_number":"0001641172-25-017037","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hepion Pharmaceuticals CFO John Brancaccio resigns; interim CFO named","event_type":"leadership","confidence":"high","bullets":["John Brancaccio resigned as CFO and director effective June 30, 2025, for personal reasons.","Kaouthar Lbiati assumes role of Interim Chief Financial Officer as of the filing date.","No permanent successor has been announced; company is a clinical-stage biotech (HEPA)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156256,"accession_number":"0001641172-25-014858","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Hepion shareholders reject reverse stock split amendment at 2025 annual meeting","event_type":"other_material","confidence":"high","bullets":["Reverse stock split proposal (1:5 to 1:20) failed with 2.25M for, 3.70M against; not approved.","All four director nominees (Brancaccio, Block, Lbiati, Purcell) elected despite majority of votes withheld.","Ratification of Grassi & Co. as auditors passed with 4.76M for vs 1.17M against.","Advisory say-on-pay failed with 162K for, 337K against.","Only 10.9M shares outstanding; broker non-votes totaled 5.46M on most proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156255,"accession_number":"0001641172-25-014320","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Hepion appoints director Kaouthar Lbiati as interim CEO effective June 16","event_type":"leadership","confidence":"high","bullets":["Dr. Kaouthar Lbiati, a board member since June 2022, appointed interim CEO effective June 16, 2025.","Initial term of 3 months; annual base salary $350,000 with $50,000 deferred until equity financing ≥$3M or departure.","Performance bonus eligible at 35% of base salary upon milestones; pro-rated bonus if terminated without cause before term end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156254,"accession_number":"0001641172-25-013048","cik":1583771,"company_name":"Hepion Pharmaceuticals, Inc.","ticker":"HEPA","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Hepion sells Rencofilstat assets to Panetta for nominal fee; stockholders get CVR milestones","event_type":"other_material","confidence":"high","bullets":["Sold all patent assets, knowhow, clinical data, and drug product for Rencofilstat to Panetta Partners for nominal amount.","Stockholders receive CVR: $500K upon FDA approval of first NDA for Rencofilstat.","Additional CVR payments: $1M if net sales exceed $350M; $3M if net sales exceed $750M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}